Efficacy and safety of vunakizumab in patients with moderate-to-severe plaque psoriasis across different regions of China: a post-hoc exploratory analysis of a phase III, randomized controlled trial

Background Vunakizumab (anti-interleukin-17A antibody) has shown favorable efficacy and safety in treating moderate-to-severe plaque psoriasis. The morbidity and severity of psoriasis vary in different regions of China.Objective This post-hoc exploratory analysis aims to investigate the efficacy and...

Celý popis

Podrobná bibliografie

Hlavní autoři:	Kejian Zhu, Qiaoli Zheng, Yingjie Zhu, Xia Wu, Hao Cheng
Médium:	Artigo
Jazyk:	Inglês
Vydáno:	Taylor & Francis Group 2025-12-01
Edice:	Journal of Dermatological Treatment
Témata:	Moderate-to-severe plaque psoriasis vunakizumab different regions of China efficacy safety
On-line přístup:	https://www.tandfonline.com/doi/10.1080/09546634.2025.2560505
Tagy:	Přidat tag Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!